前立腺がんにおけるmiR-10b-5pの役割とそのエクソソーム媒介の血管新生効果
PubMedで要約を見る
まとめ
この要約は機械生成です。マイクロRNA 10b- 5p (miR- 10b- 5p) は,ZMYND11を抑制することによって前立腺がん (PCa) の成長を誘導する. miR-10b-5pを運ぶエクソソームは,新しい血管形成を促進し,PCaのための新しい治療目標を提供します.
科学分野
- 腫瘍学
- 分子生物学
- 生物化学
背景
- 前立腺がん (PCa) は世界的な健康問題であり,革新的な治療戦略が必要である.
- マイクロRNA (miRNA) は,がんの発達と進行における役割としてますます認識されています.
研究 の 目的
- 前立腺がんにおけるmiR-10b-5pの腫瘍性作用 (PCa) を調査する.
- PCaの潜在的な診断マーカーおよび治療標的としてmiR-10b-5pを評価する.
主な方法
- TCGAのPCaデータのバイオ情報分析により,miR-10b-5pが候補腫瘍遺伝子として特定されました.
- 発現レベルは,臨床PCa標本における光 in situ 混合化 (FISH) を用いて検証された.
- 機能的測定では,miR- 10b- 5pがPCa細胞の増殖,移動,侵入に与える影響を評価した.
- デュアル・ルシフェラーゼ・レポーター・アッセイは ZMYND11を直接標的として確認した
- in vitroおよびin vivoモデルでは,PCa由来エクソソムのプロ血管新生効果を評価した.
主要な成果
- miR- 10b- 5pの発現はPCa組織と細胞系において有意に上昇し,腫瘍の攻撃性と相関していた.
- miR- 10b- 5pは腫瘍抑制剤ZMYND11を直接抑制し,PCa細胞の増殖,移動,侵入を促した.
- miR- 10b- 5pを発現するPCa細胞からのエクソソームは,強力な血管新生活性を示し,内皮管の形成と体内腫瘍の新血管化を促進した.
結論
- miR- 10b- 5pはZMYND11を標的にして前立腺がんの進行を促進する.
- miR-10b-5pを運ぶエクソソームは腫瘍血管新生に寄与する.
- miR- 10b- 5pは前立腺がんの治療における有望な新たな標的となる.
関連する概念動画
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

